Last 7 days
19.1%
Last 30 days
145.5%
Last 90 days
5656.3%
Trailing 12 Months
1270%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
BGNE | 298.0B | 1.4B | -3.25% | 8.54% | -148.7 | 210.43 | 20.37% | -37.45% |
ABBV | 279.9B | 58.1B | 4.88% | 1.38% | 23.64 | 4.82 | 3.30% | 2.55% |
REGN | 87.7B | 12.2B | 9.61% | 20.63% | 20.21 | 7.2 | -24.26% | -46.28% |
VRTX | 80.8B | 8.9B | 6.80% | 24.91% | 24.32 | 9.05 | 17.91% | 41.84% |
ALNY | 23.5B | 1.0B | -5.53% | 16.05% | -20.81 | 22.69 | 22.88% | -32.64% |
SRPT | 11.5B | 933.0M | 2.93% | 61.85% | -16.28 | 12.27 | 32.93% | -67.99% |
UTHR | 10.1B | 1.9B | -9.77% | 22.96% | 13.92 | 5.23 | 14.88% | 52.86% |
MID-CAP | ||||||||
MDGL | 4.2B | 504.0K | -19.59% | 144.55% | -14.38 | 2.5K | -66.53% | -22.12% |
RARE | 2.6B | 363.3M | -18.37% | -45.49% | -3.74 | 7.28 | 3.39% | -55.81% |
BPMC | 2.6B | 204.0M | 1.49% | -34.21% | -4.68 | 12.78 | 13.30% | 13.44% |
MRTX | 2.3B | 12.4M | -15.06% | -52.42% | -3.05 | 181.9 | - | -27.34% |
SMALL-CAP | ||||||||
CPRX | 1.7B | 214.2M | 4.81% | 93.98% | 20.42 | 7.92 | 52.10% | 110.42% |
MGNX | 412.2M | 151.9M | 1.98% | -27.23% | -3.44 | 2.71 | 96.19% | 40.75% |
CRBP | 28.6M | - | 145.52% | 1270.00% | -0.67 | 19.11 | -77.61% | 7.22% |
CYTK | 3.1M | 94.6M | -20.08% | -11.44% | -0.01 | 0.03 | 34.30% | -80.65% |
Income Statement (Last 12 Months) | (In Thousands) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 |
Revenue | -100.0% | 882 | 1,540 | 2,673 | 2,823 | |
Operating Expenses | -30.0% | 39,835 | 56,871 | - | - | - |
S&GA Expenses | 13.9% | 18,699 | 16,417 | - | - | - |
R&D Expenses | -48.0% | 16,137 | 31,062 | - | - | - |
Interest Expenses | 13.6% | -1,830 | -2,119 | - | - | - |
Net Income | 7.2% | -42,346 | -45,640 | - | - | - |
Free Cahsflow | - | -37,557 | - | - | - | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | -10.2% | 66.00 | 74.00 | 82.00 | 96.00 | 108 |
Current Assets | -10.6% | 60.00 | 67.00 | 75.00 | 88.00 | 100 |
Cash Equivalents | 36.6% | 17.00 | 12.00 | 26.00 | 57.00 | 25.00 |
Net PPE | -10.3% | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
Liabilities | 4.5% | 33.00 | 32.00 | 33.00 | 35.00 | 39.00 |
Current Liabilities | -27.6% | 13.00 | 17.00 | 16.00 | 15.00 | 17.00 |
Long Term Debt | 0% | 21.00 | 21.00 | 21.00 | 21.00 | - |
LT Debt, Current | 32.2% | 10.00 | 7.00 | 5.00 | 3.00 | - |
LT Debt, Non Current | 70.3% | 16.00 | 9.00 | 12.00 | 14.00 | 16.00 |
Shareholder's Equity | -21.4% | 33.00 | 42.00 | 49.00 | 61.00 | 69.00 |
Retained Earnings | -2.9% | -392 | -381 | -372 | -359 | -349 |
Additional Paid-In Capital | 0.4% | 425 | 423 | 422 | 420 | 419 |
Accumulated Depreciation | 7.0% | 3.00 | 3.00 | 3.00 | 2.00 | - |
Shares Outstanding | -0.1% | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
Float | - | 202 | - | - | - | - |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | 5.6% | -37.54 | -39.79 | -31.69 | -36.99 | -48.18 |
Share Based Compensation | -8.4% | 6.00 | 6.00 | 7.00 | 8.00 | 9.00 |
Cashflow From Investing | 98.9% | 30.00 | 15.00 | 21.00 | 27.00 | -73.42 |
Cashflow From Financing | -53361600.0% | -0.53 | 1* | 0.00 | 0.00 | 61.00 |
100%
100%
85.4%
Y-axis is the maximum loss one would have experienced if Corbus Pharmaceuticals Holdings was unfortunately bought at previous high price.
20.5%
1.9%
13.0%
FIve years rolling returns for Corbus Pharmaceuticals Holdings.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-15 | B. Riley Wealth Advisors, Inc. | new | - | 2,365 | 2,365 | -% |
2023-02-21 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | sold off | -100 | - | - | -% |
2023-02-14 | BOOTHBAY FUND MANAGEMENT, LLC | unchanged | - | -2,587 | 4,413 | -% |
2023-02-14 | Knoll Capital Management, LLC | sold off | -100 | -833,000 | - | -% |
2023-02-14 | Bank of New York Mellon Corp | reduced | -6.53 | -1,457 | 3,543 | -% |
2023-02-14 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | added | 68.75 | 2,394 | 17,394 | -% |
2023-02-14 | TWO SIGMA SECURITIES, LLC | new | - | 9,339 | 9,339 | -% |
2023-02-14 | Verition Fund Management LLC | sold off | -100 | -22,000 | - | -% |
2023-02-14 | TWO SIGMA ADVISERS, LP | sold off | -100 | -3,000 | - | -% |
2023-02-14 | TWO SIGMA INVESTMENTS, LP | added | 366 | 43,004 | 63,004 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Aug 24, 2022 | etf managers group, llc | 4.95% | 6,194,679 | SC 13G/A | |
Feb 14, 2022 | etf managers group, llc | 8.78% | 10,995,143 | SC 13G/A | |
Jun 01, 2021 | etf managers group, llc | 11.39% | 14,240,357 | SC 13G/A | |
May 11, 2021 | etf managers group, llc | 5.34% | 6,673,458 | SC 13G/A | |
Apr 12, 2021 | blackrock inc. | 4.5% | 5,673,664 | SC 13G/A | |
Mar 17, 2021 | etf managers group, llc | 4.80% | 5,997,343 | SC 13G/A | |
Feb 16, 2021 | etf managers group, llc | 6.96% | 5,851,347 | SC 13G/A | |
Feb 12, 2021 | etf managers group, llc | 9.28% | 7,796,166 | SC 13G/A | |
Jan 29, 2021 | blackrock inc. | 6.2% | 5,220,525 | SC 13G/A | |
Jan 11, 2021 | state street corp | 1.59% | 1,333,546 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | 1.80 -73.72% | 1.90 -72.26% | 2.19 -68.03% | 2.64 -61.46% | 3.81 -44.38% |
Current Inflation | 1.79 -73.87% | 1.89 -72.41% | 2.15 -68.61% | 2.54 -62.92% | 3.56 -48.03% |
Very High Inflation | 1.79 -73.87% | 1.87 -72.70% | 2.09 -69.49% | 2.42 -64.67% | 3.26 -52.41% |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 10, 2023 | S-8 | Employee Benefits Plan | |
Mar 07, 2023 | 8-K | Current Report | |
Mar 07, 2023 | 4 | Insider Trading | |
Mar 07, 2023 | 3 | Insider Trading | |
Mar 07, 2023 | 10-K | Annual Report | |
Mar 06, 2023 | 8-K | Current Report | |
Feb 15, 2023 | 8-K/A | Current Report | |
Feb 15, 2023 | 4 | Insider Trading | |
Feb 15, 2023 | 4 | Insider Trading | |
Feb 15, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2022-08-10 | Cohen Yuval | bought | 1,003 | 0.264 | 3,800 | chief executive officer |
2022-08-10 | Millian Craig Stuart | bought | 1,272 | 0.2545 | 5,000 | chief operating officer |
2022-08-10 | Moran Sean F. | bought | 5,198 | 0.2599 | 20,000 | chief financial officer |
2022-05-16 | Cohen Yuval | bought | 2,625 | 0.25 | 10,500 | chief executive officer |
2022-05-16 | Moran Sean F. | bought | 3,600 | 0.3 | 12,000 | chief financial officer |
2022-03-10 | Millian Craig Stuart | bought | 3,700 | 0.37 | 10,000 | chief operating officer |
2022-03-10 | Moran Sean F. | bought | 5,550 | 0.37 | 15,000 | chief financial officer |
2022-03-09 | Cohen Yuval | bought | 3,182 | 0.37 | 8,600 | chief executive officer |
2020-12-21 | Moran Sean F. | acquired | 122,500 | 1.4 | 87,500 | chief financial officer |
2020-12-21 | Moran Sean F. | sold | -153,125 | 1.75 | -87,500 | chief financial officer |
Consolidated Statements of Operations - USD ($) | 12 Months Ended | |
---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | |
Income Statement [Abstract] | ||
Revenue from awards | $ 0 | $ 881,705 |
Operating expenses: | ||
Research and development | 16,136,826 | 36,445,285 |
General and administrative | 18,698,619 | 20,425,444 |
Litigation Settlement | 5,000,000 | 0 |
Total operating expenses | 39,835,445 | 56,870,729 |
Operating loss | (39,835,445) | (55,989,024) |
Other income (expense), net: | ||
Other income (expense), net | (48,773) | 11,899,992 |
Interest income (expense), net | (2,132,091) | (1,830,486) |
Change in fair value of derivative liability | 96,842 | 663,290 |
Foreign currency exchange gain (loss), net | (427,436) | (384,198) |
Other income (expense), net | (2,511,458) | 10,348,598 |
Net loss | $ (42,346,903) | $ (45,640,426) |
Net loss per share, basic | $ (10.15) | $ (11.15) |
Net loss per share, diluted | $ (10.15) | $ (11.15) |
Weighted average number of common shares outstanding, basic | 4,170,675 | 4,094,935 |
Weighted average number of common shares outstanding, diluted | 4,170,675 | 4,094,935 |
Comprehensive loss: | ||
Net loss | $ (42,346,903) | $ (45,640,426) |
Other comprehensive income (loss): | ||
Change in unrealized gain (loss) on marketable debt securities | (63,647) | (62,445) |
Total other comprehensive income (loss) | (63,647) | (62,445) |
Total comprehensive loss | $ (42,410,550) | $ (45,702,871) |
Consolidated Balance Sheets - USD ($) | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 17,002,715 | $ 25,006,632 |
Investments | 42,194,296 | 72,640,520 |
Restricted cash | 192,475 | 192,475 |
Prepaid expenses and other current assets | 791,616 | 2,365,010 |
Total current assets | 60,181,102 | 100,204,637 |
Restricted cash | 477,425 | 477,425 |
Property and equipment, net | 1,613,815 | 2,392,696 |
Operating lease right of use assets | 3,884,252 | 4,609,110 |
Other assets | 155,346 | 46,385 |
Total assets | 66,311,940 | 107,730,253 |
Current liabilities: | ||
Notes payable | 353,323 | 767,938 |
Accounts payable | 2,173,963 | 1,782,277 |
Accrued expenses | 5,999,252 | 10,093,312 |
Derivative liability | 36,868 | 133,710 |
Operating lease liabilities, current | 1,280,863 | 1,136,948 |
Current portion of long-term debt | 2,795,669 | 3,093,344 |
Total current liabilities | 12,639,938 | 17,007,529 |
Long-term debt, net of debt discount | 15,984,426 | 15,636,275 |
Other long-term liabilities | 22,205 | 22,205 |
Operating lease liabilities, noncurrent | 4,675,354 | 5,956,217 |
Total liabilities | 33,321,923 | 38,622,226 |
Stockholders' equity | ||
Preferred stock, $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding at December 31, 2022 and December 31, 2021. See Note 13 | 0 | 0 |
Common stock, $0.0001 par value; 300,000,000 shares authorized, 4,171,297 and 4,169,631 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively | 417 | 416 |
Additional paid-in capital | 425,196,359 | 418,903,820 |
Accumulated deficit | (392,080,667) | (349,733,764) |
Accumulated other comprehensive loss | (126,092) | (62,445) |
Total stockholders’ equity | 32,990,017 | 69,108,027 |
Total liabilities and stockholders’ equity | $ 66,311,940 | $ 107,730,253 |